Discovers and develops peptide-based medicines. Focuses on treatments for gastrointestinal and metabolic diseases. Now — the numbers.
This is an established company with proven profits.
Average growth of 137% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $2.3B would still be left in the vault — a solid cushion for hard times.
The market pays 3.3× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 67% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 70% — still a thick cushion, though costs have been eating into it lately.
Over the last 4 years, sales grew about 137% a year on average.
There is $2.3B in the vault; even if every debt were paid off, $2.3B would remain.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Against everything we grade, ZLDPF lands near the top. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: ZLDPF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
Not covered, because the filings we hold do not carry it: the revenue breakdown.